Zacks Research Comments on Sanofi’s Q3 Earnings (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) – Zacks Research raised their Q3 2025 earnings estimates for Sanofi in a research note issued on Wednesday, January 22nd. Zacks Research analyst K. Shah now anticipates that the company will post earnings per share of $1.59 for the quarter, up from their prior forecast of $1.58. The consensus estimate for Sanofi’s current full-year earnings is $3.82 per share. Zacks Research also issued estimates for Sanofi’s Q1 2026 earnings at $1.06 EPS, Q2 2026 earnings at $1.05 EPS, Q4 2026 earnings at $1.20 EPS and FY2026 earnings at $4.78 EPS.

Separately, StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th.

Sanofi Trading Up 0.9 %

Shares of SNY opened at $51.98 on Friday. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $131.92 billion, a P/E ratio of 26.52, a PEG ratio of 1.19 and a beta of 0.57. The firm’s 50-day moving average is $48.61 and its two-hundred day moving average is $52.16.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. The business had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same period in the prior year, the company posted $2.55 EPS.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Franklin Resources Inc. increased its position in Sanofi by 13.1% during the third quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock worth $208,106,000 after buying an additional 395,744 shares in the last quarter. Natixis Advisors LLC boosted its stake in shares of Sanofi by 4.1% during the third quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock valued at $165,640,000 after acquiring an additional 114,133 shares during the last quarter. Raymond James & Associates increased its position in Sanofi by 4.8% during the 3rd quarter. Raymond James & Associates now owns 2,819,348 shares of the company’s stock worth $162,479,000 after purchasing an additional 129,472 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Sanofi by 20.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after purchasing an additional 399,301 shares during the last quarter. Finally, Brandes Investment Partners LP lifted its holdings in Sanofi by 8.4% in the 2nd quarter. Brandes Investment Partners LP now owns 2,122,748 shares of the company’s stock valued at $102,706,000 after purchasing an additional 165,256 shares in the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.